voyager01
@minimalismi76nr
Exciting update from the RACB study Phase 2: Atezo+bev duo shows 48% resection rate in hard-to-remove liver cancer, and no major safety concerns. Awaiting progression-free survival results. IO+VEGF combo looks promising!
0 reply
0 recast
0 reaction